Yang Kangping, Li Benjie, Xu Xuan, Yu Zilu, Lyu Xinmeng, Ren Kexin, Liu Xiangfei, Chen Shen, Li Huizi
Department of General Surgery, The Second Affiliated Hospital, Jiangxi Medical School, Nanchang University, Nanchang, PR China.
Queen Mary School, Jiangxi Medical School, Nanchang University, Nanchang, PR China.
Expert Rev Mol Diagn. 2024 Dec 9:1-12. doi: 10.1080/14737159.2024.2436391.
Overexpression of tribbles homolog 3 (TRIB3) has been reported in various cancers, yet its clinical significance remains contentious. This study aims to elucidate the association between TRIB3 overexpression and the progression and prognosis of solid tumors.
A comprehensive analysis was conducted using data from published studies and The Cancer Genome Atlas (TCGA) up to May 2023. We evaluated the impact of high TRIB3 expression on tumor malignancy and survival outcomes across different cancer types.
Seventeen studies met the inclusion criteria. Our findings revealed that TRIB3 overexpression is significantly associated with increased distant metastasis (OR = 4.01, 95% CI: 2.36-6.74, < 0.001) and advanced histological stage (OR = 2.68, 95% CI: 1.50-4.78, < 0.001). Additionally, high TRIB3 expression significantly elevated the risk of reduced overall survival (OS) in cancer patients (HR = 1.52, 95% CI: 1.05-2.20, < 0.001), indicating a poor prognosis. Analyses of TCGA data among various prognostic indicators corroborated these findings.
TRIB3 overexpression is significantly linked to malignant progression and unfavorable prognosis in diverse solid tumors. These results suggest that TRIB3 holds promise as a biomarker and therapeutic target in human cancers.
已有报道称TRIB3（tribbles同源物3）在多种癌症中过表达，但其临床意义仍存在争议。本研究旨在阐明TRIB3过表达与实体瘤进展及预后之间的关联。
利用截至2023年5月已发表研究和癌症基因组图谱（TCGA）的数据进行综合分析。我们评估了TRIB3高表达对不同癌症类型肿瘤恶性程度和生存结果的影响。
17项研究符合纳入标准。我们的研究结果显示，TRIB3过表达与远处转移增加（OR = 4.01，95%CI：2.36 - 6.74，P < 0.001）和高级别组织学分期（OR = 2.68，95%CI：1.50 - 4.78，P < 0.001）显著相关。此外，TRIB3高表达显著增加了癌症患者总生存期（OS）降低的风险（HR = 1.52，95%CI：1.05 - 2.20，P < 0.001），表明预后不良。对各种预后指标的TCGA数据分析证实了这些发现。
TRIB3过表达与多种实体瘤的恶性进展和不良预后显著相关。这些结果表明，TRIB3有望成为人类癌症中的生物标志物和治疗靶点。
